| Pharmaceutical Information |
| Drug Name |
Valrubicin |
| Drug ID |
BADD_D02330 |
| Description |
Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR. It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder. |
| Indications and Usage |
For the treatment of cancer of the bladder. |
| Marketing Status |
approved |
| ATC Code |
L01DB09 |
| DrugBank ID |
DB00385
|
| KEGG ID |
D02697
|
| MeSH ID |
C016163
|
| PubChem ID |
454216
|
| TTD Drug ID |
D07IPB
|
| NDC Product Code |
67979-001; 77391-005 |
| UNII |
2C6NUM6878
|
| Synonyms |
valrubicin | N-trifluoroacetyladriamycin 14-valerate | Valtaxin | Valstar | AD 32 | AD-32 | NSC-246131 |
|
| Chemical Information |
| Molecular Formula |
C34H36F3NO13 |
| CAS Registry Number |
56124-62-0 |
| SMILES |
CCCCC(=O)OCC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O
5)C)O)NC(=O)C(F)(F)F)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
